The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of chemotherapy (CTX) on venous thromboembolism (VTE) and prognostic implications in patients with metastatic urinary tract tumors (UTT).
 
Jorge Ramos
No Relationships to Disclose
 
Martin Francis Casey
No Relationships to Disclose
 
Simon J. Crabb
No Relationships to Disclose
 
Aristotelis Bamias
No Relationships to Disclose
 
Lauren Christine Harshman
No Relationships to Disclose
 
Yu-Ning Wong
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - eviti
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Ugo De Giorgi
No Relationships to Disclose
 
Sylvain Ladoire
No Relationships to Disclose
 
Thomas Powles
No Relationships to Disclose
 
Sumanta Kumar Pal
Honoraria - Medivation; Novartis
Consulting or Advisory Role - Aveo; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Guenter Niegisch
No Relationships to Disclose
 
Cora N. Sternberg
No Relationships to Disclose
 
Ajjai Shivaram Alva
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Dendreon
Research Funding - amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
Other Relationship - Exelixis; Medivation; Takeda
 
Andrea Necchi
No Relationships to Disclose
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Merck
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Oncogenex; Onyx
 
Matt D. Galsky
Stock and Other Ownership Interests - Dual Therapeutics
Consulting or Advisory Role - Astellas Pharma; BioMotiv; Dendreon; GlaxoSmithKline; Janssen; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
Travel, Accommodations, Expenses - Astellas Pharma; BioMotiv; Dendreon; Merck
 
Evan Y. Yu
Honoraria - Amgen; Bayer; Dendreon; Janssen; Medivation; Sanofi
Consulting or Advisory Role - Amgen; Dendreon; Janssen; Medivation; Sanofi
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); GTx (Inst); ImClone Systems (Inst); Janssen (Inst); Oncogenex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dendreon; Janssen; Medivation